Symptomtext
sibling patient who received FLUZONE QUADRIVALENT twice with no reported adverse event; Initial information received on 09-Oct-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case is linked to case 2023SA312142(CLUSTER). This case involves a 6 years old male patient who received Influenza Quadrival A-B Vaccine [Fluzone Qiv] twice with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Sep-2023, the patient received Dose 1 of suspect Influenza quadrival a-b vaccine Suspension for injection (lot number: UT8144LA) (Expiry date: 30-Jun-2024) via unknown route in unknown administration site for immunisation. On 07-Oct-2023 he also received Dose 2 of the same vaccine via unknown route in unknown administration site. On 07-Oct-2023, the patient received Influenza Quadrival A-B Vaccine twice with no reported adverse event (extra dose administered) (latency: same day). It was reported, called stating that they have sibling patient who received FLUZONE QUADRIVALENT twice and would like to know what to do moving forward and what to look for. Nurse stated that siblings came Saturday, 07Oct2023 and was given FLUZONE QUADRIVALENT The 8-month old patient was has her first flu shot 16Sept2023 and second 07Oct2023 which is just 3 weeks apart The 6-year-old patient had his first injection 08Sep2023 and the second 07Oct2023. Nurse would like to know what to look for and whether they need to revaccinate the patients. Action taken: not applicable. Outcome: Unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.